Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
1. Event-free survival at 24 months was 67.4% in the durvalumab group and 58.5% in the placebo group, with HR ...
Tag: gastric cancer
Birth cohort effects observed for increased appendiceal adenocarcinoma incidence
1. In this retrospective cohort study, age-specific incidence rates of appendiceal adenocarcinoma increased by time period. 2. Local drift for ...
#VisualAbstract: First-Line Sugemalimab Plus Chemotherapy Provides Survival Benefit in Advanced Gastric Cancer
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Endoscopic semi-blunt dissection technique safe and effective for gastric submucosal tumors
1. Use of the semi-blunt dissection technique with endoscopic resection of gastric submucosal tumours was associated with a smaller maximum ...
Astellas: Vyloy improves survival in patients with advanced gastric cancer
Vyloy plus standard-of-care chemotherapy extended overall survival in patients with advanced gastric cancer. The rate of grade 3 or higher ...
#VisualAbstract Screening for Helicobacter Pylori to Prevent Gastric Cancer with Fecal Immunochemical Tests
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
#VisualAbstract: Fruquintinib Plus Paclitaxel Improved Progression-Free Survival in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Click here to read this study in Nature Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer
1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...
#VisualAbstract: Perioperative pembrolizumab with chemotherapy for gastric and gastroesophageal junction adenocarcinoma improves pathological complete response rate compared with placebo
1. The median overall survival and event-free survival were not statistically different in the pembrolizumab group as compared to the ...
Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer
1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...